CN101642522B - Traditional Chinese medicine composition and preparation method thereof - Google Patents
Traditional Chinese medicine composition and preparation method thereof Download PDFInfo
- Publication number
- CN101642522B CN101642522B CN2009101845339A CN200910184533A CN101642522B CN 101642522 B CN101642522 B CN 101642522B CN 2009101845339 A CN2009101845339 A CN 2009101845339A CN 200910184533 A CN200910184533 A CN 200910184533A CN 101642522 B CN101642522 B CN 101642522B
- Authority
- CN
- China
- Prior art keywords
- dry powder
- rhizoma paridis
- weight portion
- extract
- radix notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 36
- 239000000843 powder Substances 0.000 claims abstract description 36
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 35
- 238000001035 drying Methods 0.000 claims abstract description 12
- 238000002481 ethanol extraction Methods 0.000 claims abstract description 4
- 239000009636 Huang Qi Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 27
- 238000000605 extraction Methods 0.000 claims description 17
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 14
- 230000036592 analgesia Effects 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 230000002785 anti-thrombosis Effects 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 13
- 239000000469 ethanolic extract Substances 0.000 abstract description 8
- 241000208152 Geranium Species 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000036407 pain Effects 0.000 abstract description 2
- 229940107666 astragalus root Drugs 0.000 abstract 3
- 238000010298 pulverizing process Methods 0.000 abstract 2
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 238000003809 water extraction Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 20
- 230000008961 swelling Effects 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 14
- 239000012567 medical material Substances 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 13
- 235000019634 flavors Nutrition 0.000 description 13
- 206010053567 Coagulopathies Diseases 0.000 description 11
- 229920001525 carrageenan Polymers 0.000 description 11
- 235000010418 carrageenan Nutrition 0.000 description 11
- 230000035602 clotting Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 210000003371 toe Anatomy 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 206010014025 Ear swelling Diseases 0.000 description 5
- 238000012449 Kunming mouse Methods 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 235000006533 astragalus Nutrition 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 241000244987 Daiswa polyphylla Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- -1 flavone compound Chemical class 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- RNKMOGIPOMVCHO-SJMVAQJGSA-N 1,3,6-trigalloyl glucose Chemical compound C([C@@H]1[C@H]([C@@H]([C@@H](O)[C@H](OC(=O)C=2C=C(O)C(O)=C(O)C=2)O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 RNKMOGIPOMVCHO-SJMVAQJGSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 241000387101 Erodium stephanianum Species 0.000 description 1
- 241001166194 Geranium wilfordii Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000365112 Monsonia angustifolia Species 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition comprising 2-3 parts by weight of astragalus root, 1-2 parts by weight of radix notoginseng, 0.8-1.2 parts by weight of geranium and 1-2 parts by weight of rhizoma paridis. The preparation method of the composition comprises the following steps: after extracting the rhizoma paridis, the astragalus root and the radix notoginseng with ethanol with the mass percent concentration of 70-90%, carrying out water extraction on medicine residues obtained after ethanol extraction and the geranium, then drying after concentrating the ethanol extract of the rhizoma paridis, the astragalus root and the radix notoginseng into an extract, pulverizing into ethanol extract dry powder, drying after concentrating the water extract into an extract, pulverizing into water extract dry powder, and finally, mixing the water extract dry powder and the ethanol extract dry powder so as to obtain the composition. The composition can be used for preparing a medicine for diminishing inflammation, relieving pain or resisting thrombus, and the medicine has obvious curative effect.
Description
Technical field
The invention belongs to field of traditional Chinese medicine pharmacy, be specifically related to a kind of Chinese medicine composition and preparation method thereof.This Chinese medicine composition has antiinflammatory, analgesia or anti thrombotic action.
Background technology
The Radix Astragali is the dry root of leguminous plant Radix Astragali Astragalus membranaceus (Fisch.) Bge. and Radix Astagali Astragalus membranaceus (Fisch.) Bge.var.mongholicus (Bge.) Hsiao the earliest; It is the key medicine of invigorating the spleen and benefiting QI, consolidating superficial resistance diuresis, detoxification evacuation of pus, expelling pus and promoting granulation; Its main active is Radix Astragali saponin and polysaccharide, and Radix Astragali saponin has antiinflammatory, blood pressure lowering, resisting myocardial ischemia, central analgesia, abirritative effect; The effect that astragalus polysaccharides has enhancing human body immunity power, improves human body anti allergic reaction ability.
Rhizoma Paridis is the dry rhizome of Liliaceae Rhizoma Paridis Paris poly-phylla Smith var.yunnanensis (Franch.) Hand.-Mazz. and Rhizoma Paridis Paris poly-phylla Smith var.chinensis (Franch.) Hara.Have the effect of heat-clearing and toxic substances removing, reducing swelling and alleviating pain, cool liver arresting convulsion, its main active is a diosgenin, has effects such as antitumor, antiinflammatory, calmness, analgesia, hemostasis.
Radix Notoginseng is the dry root and rhizome of Araliaceae Panax notoginseng (Burk.) F.H.Chen, has effects such as analgesia, antiinflammatory, strengthening by means of tonics, and its main active is arasaponin, dencichine etc., is valuable medicinal.The article of giving birth to overweight the dissipating blood stasis hemostasis, and ripe article overweight enriches blood.
Herba Erodii is the dry aerial parts of yak department of pediatrics plant yak Seedling Erodium step hanianum Willd, Herba Erodii Geranium wilfordii Maxim. or Carolina Cranesbill Herb Geranium carolinanum L.; Effect with expelling wind and removing dampness, the meridian dredging, heat-clearing and toxic substances removing, its main active are tannin, flavone compound.Tannin is a kind of water solublity polyhydric phenols with precipitating proteins characteristic; Not only have the effect of common convergence, anti-inflammation, hemostasis, anthelmintic, antidiarrheal, anti-several diseases protozoan infection property disease, also have antitumor, mutation, anti peroxidation of lipid, antiallergic action, suppress pepsin; Prevention irritability gastrointestinal damage; Blood pressure lowering, blood fat reducing improve functions such as hepatic and renal function, and the central nervous system is had sedation.
The inventor with the Radix Astragali, Radix Notoginseng, Herba Erodii and Rhizoma Paridis combination, prepares Chinese medicine composition of the present invention through long-term exploratory development, and this combination is used for antiinflammatory, analgesia or antithrombotic and has significant curative effect.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition with antiinflammatory, analgesia or anti thrombotic action.
Another object of the present invention provides the method for preparing of above-mentioned Chinese medicine composition.
The objective of the invention is to realize through following measure:
A kind of Chinese medicine composition is characterized in that said composition selects Radix Astragali 2-3 weight portion, Radix Notoginseng 1-2 weight portion, Herba Erodii 0.8-1.2 weight portion and Rhizoma Paridis 1-2 weight portion for use.
Above-mentioned composition preferably adopts Radix Astragali 2.0-2.5 weight portion, Radix Notoginseng 1.0-1.5 weight portion, Herba Erodii 1 weight portion, Rhizoma Paridis 1.5-2.0 weight portion.
The method for preparing of above-mentioned Chinese medicine composition may further comprise the steps:
A, Rhizoma Paridis, the Radix Astragali, Radix Notoginseng are used the ethanol extraction of mass percent concentration as 70-90%;
B, gained medicinal residues and Herba Erodii after the above-mentioned alcohol extraction are carried out water carry;
C, Rhizoma Paridis, the Radix Astragali, Radix Notoginseng alcohol extract are condensed into the extractum after drying, are ground into alcohol extract dry powder; The water extract is condensed into the extractum after drying, is ground into water extract dry powder;
D, with promptly getting the present composition after water extract dry powder, the alcohol extract dry powder blend.
Above-mentioned method for preparing can specifically prepare according to following steps:
A, Rhizoma Paridis, the Radix Astragali, Radix Notoginseng are used mass percent concentration is that 8 times of amounts of ethanol of 80% are extracted each 2h 2 times;
Gained medicinal residues and Herba Erodii adopt 10 times of water gagings to extract 2 times after b, the alcohol extraction, each 1h;
C, Rhizoma Paridis, the Radix Astragali, Radix Notoginseng alcohol extract are condensed into the extractum after drying, are ground into alcohol extract dry powder; The water extract is condensed into the extractum after drying, is ground into water extract dry powder;
D, with promptly getting the present composition after water extract dry powder, the alcohol extract dry powder blend.
Above-mentioned composition can add conventional adjuvant and process pharmaceutically acceptable various dosage form.
The application of described compositions in preparation antiinflammatory, analgesia or antithrombotic reagent.
The concrete preparation technology's flow process of Chinese medicine composition of the present invention is as shown in Figure 1.
Beneficial effect of the present invention: the present composition; The preferred of process conditions such as carry through alcohol extraction, water; Confirm its optimal processing parameter, found its effective site, and through pharmacodynamic experiment; Prove the effective site of aspects such as its analgesia, antiinflammatory, guaranteed the application of described compositions in preparation antiinflammatory, analgesia or antithrombotic reagent.
Adopt different preparation technologies to different raw materials in this technology, the effective ingredient of each raw material fully extracted, increased drug effect, be embodied in the following aspects:
(1) alcohol extraction process research
1, orthogonal test arrangement and result
Confirm the extraction factor level through preliminary experiment, adopt L
9(3
4) the orthogonal test calendar, carry out orthogonal test and measure the result, with dried cream yield, Astragaloside content, Rhizoma Paridis saponin I content and Panax Notoginseng saponin R
1Content is index, is that evaluation index is confirmed optimised process with the comprehensive grading.
Table 1 alcohol extraction orthogonal experiment factor level table
2, interpretation of result
With dried cream weight, Astragaloside content, Rhizoma Paridis saponin I content, Panax Notoginseng saponin R
1Content is index, chooses the soprano respectively as 100 minutes, and all the other by formula calculate: score y
i'=100-peak+y
i, then three indexs are invested different weights.In conjunction with producing actual require to give respectively dried cream weight, Rhizoma Paridis saponin I, Panax Notoginseng saponin R
1Weight coefficient is respectively 0.2, and the sweet weight coefficient of Radix Astragali first is 0.4, can be known by range analysis; Each factor is arranged as D＞C＞B＞A to the size that influences of this index; Difference that there are no significant, the level of D factor is good and bad arranges as follows: 3＞2＞1,1 and 3 horizontal tool significant differences wherein; 1 and 2,2 and 3 horizontal there was no significant differences.The level of C factor is good and bad arranges as follows: 2＞3＞1, and difference that there are no significant between each level.The level of B factor is good and bad arranges as follows: 2＞3＞1, and difference that there are no significant between each level.The level of A factor is good and bad arranges as follows: 2＞1＞3, and difference that there are no significant between each level.The technology that with the comprehensive grading is index is A
2B
2C
2D
3, consider from aspects such as production cost are consuming time, confirm that optimum process condition is A
2B
2C
3D
2, that is: the ethanol mass percentage concentration 80%, and 8 times of amounts of Rhizoma Paridis, the Radix Astragali and pseudo-ginseng weight are extracted 2 times, each 2h.
(2) extraction process by water research
1, orthogonal experiment design and result
Adopt L
9(3
4) the orthogonal test calendar, carry out orthogonal test and measure the result, be index with got dry extract yield, amino acid content (with respect to the content of taurine), be evaluation index is confirmed optimised process with the comprehensive grading.
Table 2 orthogonal test factor level table
2, Orthogonal experiment results: the optimised process A that optimizes gained
2B
1C
210 times of water gagings of gained medicinal residues and Herba Erodii medical material weight after the alcohol extraction extract 2 times, each 1h.
(3) effect experiment research
The effect of research prescribed analgesic, antiinflammatory and the several aspects of anticoagulation verifies that it cures mainly relevant pharmacodynamic action with clinical, and the effectiveness of checking new technology preparation.
1, laboratory animal
Kunming mouse (Second Military Medical University, PLA's Experimental Animal Center, male and female half and half).
2, trial drug
The present composition (preparing) (Nanjing Zhongshan Pharmaceutical Co., Ltd., each medical material series extract (Nanjing Zhongshan Pharmaceutical Co., Ltd.'s self-control, table 3.1 seen in lot number, code name) of distinguishing the flavor of according to embodiment 1 method; Sodium carboxymethyl cellulose (Shanghai chemical reagents corporation of Chinese Medicine group, lot number: F20020928); Carrageenin (sigma company, lot number: 122k1444); Sodium chloride injection (Nanjing Xiaoying Pharmaceutical Factory, lot number: 2004102603); Aspirin (Baijingyu Pharmaceutical Co., Ltd., Nanjing, lot number: 050611); Ibuprofen (Sino-America Tianjin Shike Pharmaceutical Co., Ltd., lot number: 05040122); Other reagent are analytical pure.
The table 3 medical material series extract of respectively distinguishing the flavor of
3, the foundation of animal model and experimental technique
1) animal divides into groups
Each effect experiment is respectively matched group (0.5%CMC-Na), positive drug group (aspirin), is tried drug group (present composition) according to divided into groups by the reagent thing.The used clinical drug dose,equivalent of animal is with mg/kg-mg/m
2Conversion factor converts, and in conjunction with actual, people, mice body weight are respectively in 50kg, 20g, and being converted to mice equivalence consumption by body surface area is 1.27g/kg.
2) mice acetic acid twisting method analgesic test
Get healthy kunming mice; By the body weight random packet, the clinical crude drug consumption of thing combined according to the invention gives positive drug (ibuprofen by group respectively; Dosage: 100mg/kg), blank (0.5%CMC-Na; Dosage is: the medical material series of 0.3ml/10g), respectively distinguishing the flavor of extract, the present composition (dosage is 1.27g/kg), be administered once every day, successive administration 12 days.Fasting is 12 hours before the last administration, and then behind the administration 45min, lumbar injection 0.6% acetum, 0.2mL/ are only observed and turned round the body number of times in the mice 15min.
3) carrageenin causes the inhibitory action test of rat toes swelling
Get healthy kunming mice; By the body weight random packet; The clinical crude drug consumption of thing combined according to the invention gives positive drug (aspirin, dosage 200mg/kg), blank (CMC-Na dosage 2.5g/kg), respectively distinguish the flavor of medical material series extract, the present composition (dosage is 1.27g/kg) by group respectively; Be administered once every day, successive administration 12 days.Fasting is 12 hours before the last administration, and administration is after 1 hour, and at the right back sufficient subcutaneous injection 1% carrageenin 0.03mL of mice, foot is weighed about cutting respectively behind the 4h, calculates the swelling degree.Cause scorching foot then and fully shred, in the 2mL normal saline, soaked 12 hours, the centrifugal 5min of 3000r/min gets supernatant in order to measuring prostaglandin 2 (PGE
2) content (PGE
2Content is represented with absorbance, and the content of the unit's of being scaled heavy sensation in the foot).Swelling degree=(causing scorching heavy sensation in the foot-normal heavy sensation in the foot) * normal heavy sensation in the foot of 100% ÷
4) inhibitory action of mice caused by dimethylbenzene xylene ear swelling test
Get healthy kunming mice, by the body weight random packet, gastric infusion is 6 days continuously, and fasting was spent the night in 12 hours, was administered once in the 7th day again, after 1 hour, evenly was coated with xylene 0.05mL on the two sides, front and back of mouse right ear, and left ear is left intact.Each group is taken off cervical vertebra execution mice respectively at causing scorching back 60 minutes, cuts ears and lays round auricle in the ears same area respectively with 7mm diameter card punch, and electronic balance is claimed quality.Calculate swelling degree and inhibitory rate of intumesce, relatively administration group and matched group difference condition are carried out the t check.Computing formula is:
Swelling degree (mg)=auris dextra tablet quality (mg)-left auricle quality (mg)
Inhibitory rate of intumesce=(matched group swelling degree-administration group swelling degree) ÷ matched group swelling degree * 100%.
5) capillary tube method is measured the clotting time of mice test
Get healthy kunming mice; By the body weight random packet, the clinical crude drug consumption of thing combined according to the invention gives positive drug (aspirin by group respectively; Dosage 36mg/kg), blank (0.5%CMC-Na; Dosage is: the medical material series of 0.3mL/10g), respectively distinguishing the flavor of extract, the present composition (dosage is 1.27g/kg), be administered once every day, successive administration 12 days.Fasting is 12 hours before the last administration, and 50 minutes eyeballs are got blood after the administration then, measure clotting time with capillary tube method.
4, trial test result and analysis
1) respectively the distinguish the flavor of acetic acid twisting analgesic test experimental result of medical material series extract
Result of the test is represented with writhing response number of times in the 15min, t check between statistical test employing group, and the result sees table 4.
The table 4 medical material series extract acetic acid twisting analgesic test experimental result of respectively distinguishing the flavor of
Annotate: * *: P＜0.01; Compare (t check) with matched group.
Experimental result shows that D group mouse writhing stoichiometric number and matched group relatively do not have significant difference (P＞0.05); All the other each groups all relatively have utmost point significant difference (P＜0.01) with matched group.
2) respectively the distinguish the flavor of carrageenin of medical material series extract causes the inhibitory action result of the test of mice toes swelling
Result of the test is with swelling degree (%) expression, and t checks between statistical test employing group, and the result sees table 5.
Respectively the distinguish the flavor of carrageenin of medical material series extract of table 5 causes the inhibitory action result of the test of mice toes swelling
Annotate: *: P＜0.05 * *: P＜0.01; Compare (t check) with matched group.
Result of the test shows; The inhibitory action and the matched group of the carrageenin toes swelling of B group relatively have utmost point significant difference (P＜0.01); Relatively there were significant differences (P＜0.05) for the inhibitory action of the carrageenin toes swelling of C group, D group, E group, F group and matched group, and the inhibitory action and the matched group of the carrageenin toes swelling of A group relatively do not have significant difference.
3) respectively the distinguish the flavor of inhibitory action test of mice caused by dimethylbenzene xylene ear swelling of medical material series extract
Result of the test is with swelling degree (%) expression, and t checks between statistical test employing group, and the result sees table 6.
The table 6 medical material series extract xylol of respectively distinguishing the flavor of causes the inhibitory action result of the test of mice ear
Annotate: *: P＜0.05, * *: P＜0.01; Compare (t check) with matched group
The result shows; The ear swelling degree and the matched group of B group, E group and F group relatively have utmost point significant difference (P＜0.01); Relatively there were significant differences (P＜0.05) for the ear swelling degree of C group and matched group, and the ear swelling degree and the matched group of A group and D group relatively do not have significant difference (P＞0.05).
4) respectively the distinguish the flavor of capillary tube method of medical material series extract is measured the clotting time of mice result of the test
Experimental result representes that with clotting time the result sees table 7.
The table 7 medical material series extract capillary tube method of respectively distinguishing the flavor of is measured the clotting time of mice result of the test
Annotate: *: P＜0.05, * *: P＜0.01; Compare (t check) with matched group
The result shows; The clotting time and the matched group of C group, E group and F group relatively have utmost point significant difference (P＜0.01); Relatively there were significant differences (P＜0.05) for the clotting time of B group and matched group, and the clotting time and the matched group of all the other each groups relatively do not have significant difference (P＞0.05).
5, present composition drug effect confirmatory experiment result
1) acetic acid twisting method mice analgesic test
Result of the test is an index with writhing response number of times in the 15min, t check between statistics employing group, and the result sees table 8.
Table 8 present composition acetic acid twisting method mice analgesic test experimental result
Annotate: * *: P＜0.01, compare (t check) with matched group;
The result shows that more all there were significant differences for the mouse writhing stoichiometric number of ibuprofen, the present composition and matched group (P＜0.01).
2) carrageenin causes the inhibitory action result of the test of mice toes swelling
Experimental result shows that with the swelling kilsyth basalt result sees table 9.
Table 9 present composition on Carrageenan causes the inhibitory action experimental result of mice toes swelling
Annotate: * *: P＜0.01; Compare (t check) with matched group;
The result shows that the inhibitory action of the carrageenin toes swelling of aspirin, the present composition and matched group relatively have utmost point significant difference (P＜0.01).
3) capillary tube method is measured the clotting time of mice result of the test
Experimental result representes that with clotting time the result sees table 10.
Table 10 present composition capillary tube method is measured the clotting time of mice result of the test
Annotate: * *: P＜0.01, compare (t check) with matched group;
The medicine efficacy screening experimental result shows that the water extract of Rhizoma Paridis Radix Astragali ethanol extract and medicinal residues thereof, Radix Notoginseng micropowder, Herba Erodii water extract are all having remarkable result aspect antiinflammatory, analgesia, the anticoagulation; The Radix Notoginseng ethanol extract has analgesic activity; The Herba Erodii ethanol extract causes in the scorching test at foot fork dish glue has positive effect.Through medicine efficacy screening test, clear and definite or verified and medicinal part and the pharmacological action of the Radix Astragali, Rhizoma Paridis, Radix Notoginseng, Herba Erodii can be used for preparing antiinflammatory, analgesia or antithrombotic medicine to have significant curative effect.
Description of drawings
Fig. 1 is a present composition preparation technology flow chart.
The specific embodiment
Embodiment 1
Prescription:
Radix Astragali 200g, Radix Notoginseng 100g, Herba Erodii 100g, Rhizoma Paridis 150g;
Preparation technology:
1, alcohol extraction: it is 80% ethanol that Rhizoma Paridis, the Radix Astragali, Radix Notoginseng are added mass percent concentration, and consumption is 8 times of amounts of Rhizoma Paridis, the Radix Astragali, three seven weight, extracts 2 times, each 2h;
2, water is carried: gained medicinal residues and Herba Erodii adopt 10 times of water gagings of medicinal residues and Herba Erodii weight to extract 2 times after the alcohol extraction, each 1h;
3, mix, dry, pulverize: Rhizoma Paridis, the Radix Astragali, Radix Notoginseng alcohol extract are condensed into behind the extractum 60 ℃ of vacuum dryings, are ground into 120 order dry powder; The water extract is condensed into 60 ℃ of vacuum dryings behind the extractum, is ground into 120 order dry powder, and is subsequent use;
4, granulate:, recharge capsule processing granule after water extract dry powder, the alcohol extract dry powder blend.
Embodiment 2
Prescription:
Radix Astragali 250g, Radix Notoginseng 150g, Herba Erodii 100g, Rhizoma Paridis 200g;
Method for preparing:
1, alcohol extraction: Rhizoma Paridis, the Radix Astragali, Radix Notoginseng are added 6 times of amounts of 70% ethanol extract each 1.5h 3 times;
2, water is carried: gained medicinal residues and Herba Erodii adopt 8 times of water gagings to extract 3 times after the alcohol extraction, each 1.5h;
3, mix, dry, pulverize: Rhizoma Paridis, the Radix Astragali, Radix Notoginseng alcohol extract are condensed into behind the extractum 60 ℃ of vacuum dryings, are ground into 120 order dry powder; The water extract is condensed into 60 ℃ of vacuum dryings behind the extractum, is ground into 120 order dry powder, and is subsequent use;
4, granulate: with processing granule after water extract dry powder and the alcohol extract dry powder blend, tabletting again.
Embodiment 3
Prescription:
Radix Astragali 225g, Radix Notoginseng 125g, Herba Erodii 80g, Rhizoma Paridis 175g;
Method for preparing:
1, alcohol extraction: Rhizoma Paridis, the Radix Astragali, Radix Notoginseng are added 10 times of amounts of 90% ethanol extract each 1h 1 time;
2, water is carried: gained medicinal residues and Herba Erodii adopt 12 times of water gagings to extract 1 time after the alcohol extraction, each 1h;
3, mix, dry, pulverize: Rhizoma Paridis, the Radix Astragali, Radix Notoginseng alcohol extract are condensed into behind the extractum 60 ℃ of vacuum dryings, are ground into 120 order dry powder; The water extract is condensed into 60 ℃ of vacuum dryings behind the extractum, is ground into 120 order dry powder, and is subsequent use;
4, with processing oral liquid after water extract dry powder, the alcohol extract dry powder blend.
The present composition is used in preparation antiinflammatory, analgesia or antithrombotic reagent.
Claims (5)
1. a Chinese medicine composition is characterized in that the said composition crude drug is Radix Astragali 2-3 weight portion, Radix Notoginseng 1-2 weight portion, Herba Erodii 0.8-1.2 weight portion and Rhizoma Paridis 1-2 weight portion; This Chinese medicine composition prepares through following method:
A, Rhizoma Paridis, the Radix Astragali, Radix Notoginseng are used the ethanol extraction of mass percent concentration as 70-90%;
B, gained medicinal residues and Herba Erodii after the above-mentioned alcohol extraction are carried out water carry;
C, Rhizoma Paridis, the Radix Astragali, Radix Notoginseng alcohol extract are condensed into the extractum after drying, are ground into alcohol extract dry powder; The water extract is condensed into the extractum after drying, is ground into water extract dry powder;
D, water extract dry powder, alcohol extract dry powder blend are promptly got compositions.
2. Chinese medicine composition according to claim 1 is characterized in that the said composition crude drug is Radix Astragali 2.0-2.5 weight portion, Radix Notoginseng 1.0-1.5 weight portion, Herba Erodii 1 weight portion and Rhizoma Paridis 1.5-2.0 weight portion.
3. the method for preparing of a Chinese medicine composition is characterized in that this method may further comprise the steps:
Get Radix Astragali 2-3 weight portion, Radix Notoginseng 1-2 weight portion, Herba Erodii 0.8-1.2 weight portion and Rhizoma Paridis 1-2 weight portion,
A, Rhizoma Paridis, the Radix Astragali, Radix Notoginseng are used the ethanol extraction of mass percent concentration as 70-90%;
B, gained medicinal residues and Herba Erodii after the above-mentioned alcohol extraction are carried out water carry;
C, Rhizoma Paridis, the Radix Astragali, Radix Notoginseng alcohol extract are condensed into the extractum after drying, are ground into alcohol extract dry powder; The water extract is condensed into the extractum after drying, is ground into water extract dry powder;
D, water extract dry powder, alcohol extract dry powder blend are promptly got compositions.
4. the method for preparing of Chinese medicine composition according to claim 3 is characterized in that this method specifically prepares according to following steps:
A, Rhizoma Paridis, the Radix Astragali, Radix Notoginseng are used mass percent concentration is that 8 times of amounts of ethanol of 80% are extracted each 2h 2 times;
Gained medicinal residues and Herba Erodii adopt 10 times of water gagings to extract 2 times after b, the alcohol extraction, each 1h;
C, Rhizoma Paridis, the Radix Astragali, Radix Notoginseng alcohol extract are condensed into the extractum after drying, are ground into alcohol extract dry powder; The water extract is condensed into the extractum after drying, is ground into water extract dry powder;
D, water extract dry powder, alcohol extract dry powder blend are promptly got compositions.
5. the application of the described compositions of claim 1 in preparation antiinflammatory, analgesia or antithrombotic reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101845339A CN101642522B (en) | 2009-08-28 | 2009-08-28 | Traditional Chinese medicine composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101845339A CN101642522B (en) | 2009-08-28 | 2009-08-28 | Traditional Chinese medicine composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101642522A CN101642522A (en) | 2010-02-10 |
| CN101642522B true CN101642522B (en) | 2012-01-25 |
Family
ID=41654682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101845339A Active CN101642522B (en) | 2009-08-28 | 2009-08-28 | Traditional Chinese medicine composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101642522B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103989772A (en) * | 2014-06-03 | 2014-08-20 | 孙忠强 | Traditional Chinese medicament for treating skin ulcer and reducing scar formation and preparation process thereof |
-
2009
- 2009-08-28 CN CN2009101845339A patent/CN101642522B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101642522A (en) | 2010-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285231B (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN101239112B (en) | Chinese medicinal composition for regulating blood fat and preparation thereof | |
| CN101862413B (en) | Chinese medicinal preparation for treating type-2 diabetes and preparation method thereof | |
| CN101816739B (en) | Chinese medicinal composition and preparation method thereof | |
| CN101524471A (en) | Pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN101347605B (en) | Traditional Chinese medicine composition for treating gout and preparation method and application thereof | |
| CN101108225A (en) | Diabetes treating capsule dose and technique of preparing the same | |
| CN101041010A (en) | Medicine compound for treating diabetes and its preparation | |
| CN102247479A (en) | Antitumor strong medicine and preparation method thereof | |
| CN101642522B (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN105998651A (en) | Compound traditional Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN101953949A (en) | Chinese medicinal composition for treating allergic rhinitis | |
| CN113209194B (en) | Composition for treating chronic gastritis and preparation method and application thereof | |
| CN103446384A (en) | Traditional Chinese medicine composition for decreasing blood sugar | |
| CN103070909B (en) | Three stilbene soft capsules and preparation method thereof | |
| CN102552711B (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN101543597A (en) | Medicine composition for nourishing spleen and kidney and building up healthful vital energy and preparation method thereof | |
| CN110237119A (en) | A kind of pharmaceutical composition that treating mucous membrane of mouth class disease and preparation method and purposes | |
| CN101474258A (en) | Ficus microcarpa var.pusillifolia extract, extracting method and application of the extract | |
| CN101156892A (en) | A preparation method of active component composition of antineoplastic improving phylactic power | |
| CN104306784A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis as well as preparation method and application thereof | |
| CN104644651A (en) | Applications of 20(R)-ginsenoside Rg3 in preparation of anti-aging drugs | |
| CN103961551A (en) | Traditional Tibetan medicine for treating diabetes | |
| CN104055963A (en) | Fat loss traditional Chinese medicine composition and preparation method thereof | |
| CN101322757A (en) | Medicament composition for treating diabetes and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A traditional Chinese medicine composition and its preparation method Granted publication date: 20120125 Pledgee: Industrial and Commercial Bank of China Co.,Ltd. Nanjing Zidong Sub branch Pledgor: NANJING ZHONGSHAN PHARMACEUTICAL Co.,Ltd. Registration number: Y2024980000139 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |